PT2146745E - Anticorpo pentaespecífico - Google Patents

Anticorpo pentaespecífico Download PDF

Info

Publication number
PT2146745E
PT2146745E PT87459319T PT08745931T PT2146745E PT 2146745 E PT2146745 E PT 2146745E PT 87459319 T PT87459319 T PT 87459319T PT 08745931 T PT08745931 T PT 08745931T PT 2146745 E PT2146745 E PT 2146745E
Authority
PT
Portugal
Prior art keywords
penta
specific antibody
antibody
specific
Prior art date
Application number
PT87459319T
Other languages
English (en)
Inventor
Volker Germaschewski
Stephanie Jane Clegg
Eric Dobrzynski
Jonathan H Ellis
Alexis Paul Godillot
Zdenka Ludmila Jonak
John R White
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PT2146745E publication Critical patent/PT2146745E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
PT87459319T 2007-04-17 2008-04-16 Anticorpo pentaespecífico PT2146745E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91222907P 2007-04-17 2007-04-17
US4413208P 2008-04-11 2008-04-11

Publications (1)

Publication Number Publication Date
PT2146745E true PT2146745E (pt) 2015-10-14

Family

ID=39872910

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87459319T PT2146745E (pt) 2007-04-17 2008-04-16 Anticorpo pentaespecífico

Country Status (30)

Country Link
US (3) US8496932B2 (pt)
EP (1) EP2146745B1 (pt)
JP (1) JP5441885B2 (pt)
KR (1) KR101560841B1 (pt)
CN (1) CN101687035B (pt)
AU (1) AU2008243049B2 (pt)
BR (1) BRPI0810250A8 (pt)
CA (1) CA2684626C (pt)
CL (1) CL2008001071A1 (pt)
CO (1) CO6251323A2 (pt)
CR (1) CR11116A (pt)
CY (1) CY1116671T1 (pt)
DK (1) DK2146745T3 (pt)
DO (1) DOP2009000236A (pt)
EA (1) EA024621B1 (pt)
ES (1) ES2547475T3 (pt)
HK (1) HK1136970A1 (pt)
HR (1) HRP20150937T1 (pt)
HU (1) HUE027584T2 (pt)
IL (1) IL201440A (pt)
MA (1) MA31310B1 (pt)
MX (1) MX2009011153A (pt)
MY (1) MY150525A (pt)
NZ (1) NZ580239A (pt)
PE (1) PE20090302A1 (pt)
PL (1) PL2146745T3 (pt)
PT (1) PT2146745E (pt)
SI (1) SI2146745T1 (pt)
TW (1) TWI473815B (pt)
WO (1) WO2008130969A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
CA2783563A1 (en) 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
CA2789416A1 (en) * 2010-02-09 2011-08-18 Glaxosmithkline Llc Novel uses
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP6211597B2 (ja) * 2012-05-01 2017-10-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規抗体
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
AU2014248636B2 (en) 2013-03-12 2017-03-30 Decimmune Therapeutics, Inc. Humanized anti-N2 antibodies
JO3580B1 (ar) 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
US9290570B2 (en) 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP2796875B8 (en) * 2013-04-23 2020-11-25 Albert-Ludwigs-Universität Freiburg Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
KR20160021125A (ko) * 2013-05-17 2016-02-24 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스) 항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019036605A2 (en) * 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
MX2020009296A (es) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
AU2019239568A1 (en) * 2018-03-23 2020-09-17 Board Of Regents, The University Of Texas System Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
CA3092695A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
US11827709B2 (en) * 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20220080044A1 (en) * 2020-09-14 2022-03-17 National Yang-Ming University Method for preventing or treating peripheral arterial occlusive disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
JP4423680B2 (ja) * 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
CN1547590A (zh) * 2000-10-13 2004-11-17 ¸ 人源化抗-LT-β-R抗体
EP1414860B1 (en) 2001-04-26 2009-12-30 Dako Denmark A/S Anti-glycated hemoglobin pan-specific monoclonal antibody
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
AU2003299641C1 (en) 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
JPWO2004060919A1 (ja) * 2002-12-26 2006-05-11 中外製薬株式会社 ヘテロ受容体に対するアゴニスト抗体
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20070014720A1 (en) * 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
ES2452115T3 (es) * 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains

Also Published As

Publication number Publication date
EA024621B1 (ru) 2016-10-31
MA31310B1 (fr) 2010-04-01
BRPI0810250A2 (pt) 2014-10-14
CN101687035B (zh) 2013-06-12
JP2010524469A (ja) 2010-07-22
KR101560841B1 (ko) 2015-11-11
HRP20150937T1 (hr) 2015-10-09
ES2547475T3 (es) 2015-10-06
US20080262203A1 (en) 2008-10-23
CR11116A (es) 2010-03-22
EA200970954A1 (ru) 2010-08-30
TWI473815B (zh) 2015-02-21
WO2008130969A2 (en) 2008-10-30
HUE027584T2 (en) 2016-11-28
PL2146745T3 (pl) 2015-11-30
CY1116671T1 (el) 2017-03-15
EP2146745A4 (en) 2011-11-30
HK1136970A1 (en) 2010-07-16
US20110229475A1 (en) 2011-09-22
IL201440A0 (en) 2010-06-16
PE20090302A1 (es) 2009-04-03
US8496932B2 (en) 2013-07-30
IL201440A (en) 2016-08-31
EP2146745B1 (en) 2015-06-17
EP2146745A2 (en) 2010-01-27
SI2146745T1 (sl) 2015-10-30
BRPI0810250A8 (pt) 2017-02-21
AU2008243049A1 (en) 2008-10-30
JP5441885B2 (ja) 2014-03-12
MX2009011153A (es) 2009-10-30
DOP2009000236A (es) 2009-11-15
CA2684626C (en) 2014-11-04
CA2684626A1 (en) 2008-10-30
CN101687035A (zh) 2010-03-31
DK2146745T3 (en) 2015-09-14
AU2008243049B2 (en) 2011-04-21
US20140010807A1 (en) 2014-01-09
TW200906855A (en) 2009-02-16
NZ580239A (en) 2012-07-27
WO2008130969A3 (en) 2008-12-18
CL2008001071A1 (es) 2009-05-22
CO6251323A2 (es) 2011-02-21
US8828384B2 (en) 2014-09-09
MY150525A (en) 2014-01-30
KR20100020946A (ko) 2010-02-23

Similar Documents

Publication Publication Date Title
HK1136970A1 (en) Penta-specific antibody
HK1214947A1 (zh) 抗體製劑
GB0708002D0 (en) Antibodies
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
IL234081B (en) Antibody binds cd3–epsilon in different species
ZA201102119B (en) Improved antibody libraies
SI2200700T1 (sl) Nova protitelesa
HK1146728A1 (en) Modified antibody constant region
IL201340A (en) Antidote 3dc - epsilon in various species
GB0615662D0 (en) Antibody
EP2077859A4 (en) ANTIBODY FORMULATION
GB0821100D0 (en) Antibodies
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
IL205073A0 (en) Anti-bst2 antibody
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0718737D0 (en) Antibodies
GB0702888D0 (en) Novel Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
EP2015785A4 (en) ANTIGEN AGRM2
GB0911770D0 (en) Antibody
GB0724185D0 (en) Antibodies